cyclosporine micro-emulsion
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients
Conditions
Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients
Trial Timeline
Feb 1, 2004 → Oct 1, 2005
NCT ID
NCT00150085About cyclosporine micro-emulsion
cyclosporine micro-emulsion is a approved stage product being developed by Novartis for Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients. The current trial status is terminated. This product is registered under clinical trial identifier NCT00150085. Target conditions include Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00150085 | Approved | Terminated |